scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1009746529 |
P356 | DOI | 10.1186/1748-717X-8-58 |
P932 | PMC publication ID | 3610192 |
P698 | PubMed publication ID | 23497695 |
P2093 | author name string | Sarah Laing | |
Anatoly Dritschilo | |||
Sean P Collins | |||
Kathryn L Taylor | |||
Brian T Collins | |||
John H Lynch | |||
Joy S Kim | |||
Keith Kowalczyk | |||
Leonard N Chen | |||
Simeng Suy | |||
Siyuan Lei | |||
Nancy A Dawson | |||
Eric K Oermann | |||
Viola Chen | |||
Gerald P Batipps | |||
Heather N Hanscom | |||
Kevin G McGeagh | |||
Pranay Krishnan | |||
Gaurav Bandi | |||
John Pahira | |||
Sunghae Uhm | |||
Andrew W Ju | |||
P2860 | cites work | A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity | Q29547290 |
Stereotactic body radiotherapy for organ-confined prostate cancer | Q33528163 | ||
The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association | Q33846043 | ||
Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation | Q34193483 | ||
The International Index of Erectile Function (IIEF): a state-of-the-science review | Q34769477 | ||
Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: implications for focal therapy. | Q36127793 | ||
The radiobiology of prostate cancer including new aspects of fractionated radiotherapy | Q36217139 | ||
Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer | Q36604355 | ||
Hypofractionation for prostate cancer: a critical review | Q37033108 | ||
Intrafractional motion of the prostate during hypofractionated radiotherapy | Q37301004 | ||
Sexual function after stereotactic body radiotherapy for prostate cancer: results of a prospective clinical trial | Q37688380 | ||
A survey of stereotactic body radiotherapy use in the United States | Q39771088 | ||
Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes | Q41775778 | ||
Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy | Q42555504 | ||
Late gastrointestinal and urogenital side-effects after radiotherapy--incidence and prevalence. Subgroup-analysis within the prospective Austrian-German phase II multicenter trial for localized prostate cancer | Q44178299 | ||
Erectile aid use by men treated for localized prostate cancer | Q44784365 | ||
Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results | Q44927559 | ||
Predictors of response to sildenafil citrate following radiation therapy for prostate cancer | Q46125033 | ||
Urinary symptom flare in 712 125I prostate brachytherapy patients: long-term follow-up | Q46158698 | ||
Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer | Q46224660 | ||
Dose gradient near target-normal structure interface for nonisocentric CyberKnife and isocentric intensity-modulated body radiotherapy for prostate cancer | Q46343237 | ||
Comparison of validated instruments measuring sexual function in men. | Q46377824 | ||
Posttreatment complications of early-stage prostate cancer patients: brachytherapy versus three-dimensional conformal radiation therapy | Q46559971 | ||
Treatment of erectile dysfunction following therapy for clinically localized prostate cancer: patient reported use and outcomes from the Surveillance, Epidemiology, and End Results Prostate Cancer Outcomes Study | Q46592554 | ||
Use of medications or devices for erectile dysfunction among long-term prostate cancer treatment survivors: potential influence of sexual motivation and/or indifference | Q48439178 | ||
Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer | Q48837209 | ||
Urinary toxicity after high dose intensity modulated radiotherapy as primary therapy for prostate cancer | Q49137789 | ||
Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. | Q52017308 | ||
Erectile function after prostate brachytherapy. | Q53273439 | ||
Urinary symptom flare following I-125 prostate brachytherapy. | Q53300115 | ||
Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality. | Q53505973 | ||
Temporal resolution of urinary morbidity following prostate brachytherapy | Q73661199 | ||
An analysis of erectile function after intensity modulated radiation therapy for localized prostate carcinoma | Q79452001 | ||
Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis | Q80195189 | ||
Quality of life and satisfaction with outcome among prostate-cancer survivors | Q80917895 | ||
PSA kinetics and PSA bounce following permanent seed prostate brachytherapy | Q81298448 | ||
PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time | Q81328456 | ||
Long-term urinary sequelae following 125iodine prostate brachytherapy | Q81588069 | ||
Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial | Q82966826 | ||
Time of decline in sexual function after external beam radiotherapy for prostate cancer | Q83733536 | ||
P921 | main subject | adaptive radiation therapy | Q180507 |
prostate cancer | Q181257 | ||
P304 | page(s) | 58 | |
P577 | publication date | 2013-03-13 | |
P1433 | published in | Radiation Oncology | Q2313370 |
P1476 | title | Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience | |
P478 | volume | 8 |
Q42250155 | A Phase II Study of Stereotactic Body Radiation Therapy for Low-Intermediate-High-Risk Prostate Cancer Using Helical Tomotherapy: Dose-Volumetric Parameters Predicting Early Toxicity |
Q38198096 | A clinical review on extreme hypofractionated stereotactic body radiation therapy for localized prostate cancer using nonrobotic linear accelerators |
Q92531197 | A treatment planning study comparing IMRT techniques and cyber knife for stereotactic body radiotherapy of low-risk prostate carcinoma |
Q41821780 | Acute Urinary Morbidity Following Stereotactic Body Radiation Therapy for Prostate Cancer with Prophylactic Alpha-Adrenergic Antagonist and Urethral Dose Reduction |
Q33659901 | Clinical characteristics and management of late urinary symptom flare following stereotactic body radiation therapy for prostate cancer |
Q38372450 | Clinical trials of stereotactic ablative radiotherapy for prostate cancer: updates and future direction |
Q64988846 | Comparison of Late Urinary Symptoms Following SBRT and SBRT with IMRT Supplementation for Prostate Cancer. |
Q48308100 | Comparison of multileaf collimator and conventional circular collimator systems in Cyberknife stereotactic radiotherapy |
Q90646730 | Comparison of rectal dose reduction by a hydrogel spacer among 3D conformal radiotherapy, volumetric-modulated arc therapy, helical tomotherapy, CyberKnife and proton therapy |
Q42638497 | Complementary and alternative medicine use and disclosure amongst Australian radiotherapy patients |
Q48736026 | Conventionally Fractionationed Volumetric Arc Therapy versus Hypofractionated Stereotactic Body Radiotherapy: Quality of Life, Side Effects, and Prostate-Specific Antigen Kinetics in Localized Prostate Cancer |
Q90429894 | Discovery of Metabolic Biomarkers Predicting Radiation Therapy Late Effects in Prostate Cancer Patients |
Q55425041 | Dosimetric Implications of Computerised Tomography-Only versus Magnetic Resonance-Fusion Contouring in Stereotactic Body Radiotherapy for Prostate Cancer. |
Q46838608 | Dosimetric and radiobiological comparison of Cyberknife and Tomotherapy in stereotactic body radiotherapy for localized prostate cancer |
Q37175207 | Dosimetric benefits of hemigland stereotactic body radiotherapy for prostate cancer: implications for focal therapy |
Q38550590 | Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer |
Q64228389 | Early Tolerance Outcomes of Stereotactic Hypofractionated Accelerated Radiation Therapy Concomitant with Pelvic Node Irradiation in High-risk Prostate Cancer |
Q38677828 | Erectile Function after Stereotactic Body Radiotherapy for Localized Prostate Cancer |
Q38276603 | Evolution of hypofractionated accelerated radiotherapy for prostate cancer - the sunnybrook experience |
Q41633448 | First Australian experience of treating localised prostate cancer patients with CyberKnife stereotactic radiotherapy: early PSA response, acute toxicity and quality of life. |
Q35174871 | Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer |
Q57280845 | Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline |
Q38746814 | Hypofractionated helical tomotherapy (75 Gy at 2.5 Gy per fraction) for localized prostate cancer: long-term analysis of gastrointestinal and genitourinary toxicity |
Q39456165 | Hypofractionated image guided radiation therapy followed by prostate seed implant boost for men with newly diagnosed intermediate and high risk adenocarcinoma of the prostate: Preliminary results of a phase 2 prospective study |
Q26823218 | Hypofractionated radiation therapy for prostate cancer: biologic and technical considerations |
Q37547386 | Hypofractionated radiotherapy for localized prostate cancer |
Q38863898 | Hypofractionated radiotherapy for organ-confined prostate cancer: is less more? |
Q38283897 | Hypofractionated radiotherapy for prostate cancer. |
Q38780363 | Hypofractionated stereotactic body radiotherapy for localized prostate cancer - first Nordic clinical experience |
Q37551757 | Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinoma |
Q40959958 | Image-guided hypofractionated proton beam therapy for low-risk prostate cancer: Analysis of quality of life and toxicity, PCG GU 002. |
Q42953465 | Improved irritative voiding symptoms 3 years after stereotactic body radiation therapy for prostate cancer |
Q48937281 | Initial experience with stereotactic body radiation therapy for localized prostate cancer using helical tomotherapy. |
Q37627132 | Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity |
Q42364887 | Interfraction Anatomical Variability Can Lead to Significantly Increased Rectal Dose for Patients Undergoing Stereotactic Body Radiotherapy for Prostate Cancer |
Q92839938 | Isolation and identification of cancer stem cells from PC3 human prostate carcinoma cell line |
Q39007067 | Late urinary toxicity modeling after stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer |
Q92323677 | Linac-based stereotactic body radiation therapy vs moderate hypofractionated radiotherapy in prostate cancer: propensity-score based comparison of outcome and toxicity |
Q41816565 | Long-term intra-fractional motion of the prostate using hydrogel spacer during Cyberknife® treatment for prostate cancer--a case report |
Q59335949 | Long-term results and PSA kinetics after robotic SBRT for prostate cancer: multicenter retrospective study in Korea (Korean radiation oncology group study 15-01) |
Q91436232 | Moderate hypofractionation and stereotactic body radiation therapy in the treatment of prostate cancer |
Q48238146 | Moderate hypofractionation for prostate cancer: A user's guide. |
Q33985573 | Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer |
Q37671472 | Optimal planning strategy among various arc arrangements for prostate stereotactic body radiotherapy with volumetric modulated arc therapy technique |
Q41985869 | Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer |
Q41953259 | Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer |
Q33851417 | Patient-reported urinary incontinence following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer |
Q38158080 | Potency preservation following stereotactic body radiation therapy for prostate cancer |
Q39078034 | Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer. |
Q34748877 | Proctitis following stereotactic body radiation therapy for prostate cancer |
Q65001493 | Prostate irradiation with focal dose escalation to the intraprostatic dominant nodule: a systematic review. |
Q37522643 | Prostate-specific antigen bounce following stereotactic body radiation therapy for prostate cancer |
Q35827490 | Prostate-specific antigen kinetics after primary stereotactic body radiation therapy using CyberKnife for localized prostate cancer |
Q36387814 | Prostate-specific antigen kinetics after stereotactic body radiotherapy as monotherapy or boost after whole pelvic radiotherapy for localized prostate cancer |
Q51614445 | Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy versus conventionally fractionated external beam radiotherapy for low- and intermediate-risk prostate cancer. |
Q34413524 | Quality of Life and Toxicity after SBRT for Organ-Confined Prostate Cancer, a 7-Year Study |
Q38172209 | Rationale for stereotactic body radiation therapy in treating patients with oligometastatic hormone-naïve prostate cancer |
Q37116581 | Rectal endoscopy findings following stereotactic body radiation therapy for clinically localized prostate cancer |
Q41276603 | Reducing rectal injury in men receiving prostate cancer radiation therapy: current perspectives |
Q41836348 | Relationship between two year PSA nadir and biochemical recurrence in prostate cancer patients treated with iodine-125 brachytherap |
Q97540700 | Risk of erectile dysfunction after modern radiotherapy for intact prostate cancer |
Q38677018 | SBRT and extreme hypofractionation: A new era in prostate cancer treatments? |
Q34487782 | SBRT for the Primary Treatment of Localized Prostate Cancer: The Effect of Gleason Score, Dose and Heterogeneity of Intermediate Risk on Outcome Utilizing 2.2014 NCCN Risk Stratification Guidelines |
Q36009944 | Sexual, irritative, and voiding outcomes, following stereotactic body radiation therapy for prostate cancer |
Q88640217 | Short-term high precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion: ad interim analysis and preliminary results of Phase II trial AIRC-IG-13218 |
Q38982350 | Simple diagrammatic method to delineate male urethra in prostate cancer radiotherapy: an MRI based approach |
Q34575533 | Stereotactic Body Radiation Therapy for Prostate Cancer: Review of Experience of a Multicenter Phase I/II Dose-Escalation Study |
Q35233601 | Stereotactic Body Radiation Therapy for Prostate Cancer: What is the Appropriate Patient-Reported Outcome for Clinical Trial Design? |
Q36426682 | Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry |
Q44514013 | Stereotactic Body Radiotherapy for Low-Risk Prostate Cancer: A Ten-Year Analysis |
Q38268325 | Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)). |
Q90041948 | Stereotactic body radiation therapy in primary hepatocellular carcinoma: current status and future directions |
Q37702326 | Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity |
Q38243077 | Stereotactic body radiotherapy for primary prostate cancer: a systematic review |
Q92374044 | Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes |
Q42702939 | Stereotactic radiotherapy for prostate cancer: A review and future directions |
Q37159100 | The Impact of Obesity on Patient Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer |
Q30443893 | The RSSearch™ Registry: patterns of care and outcomes research on patients treated with stereotactic radiosurgery and stereotactic body radiotherapy |
Q39200876 | The Role of Hypofractionated Radiotherapy in Prostate Cancer |
Q37510070 | The benefit of using bladder sub-volume equivalent uniform dose constraints in prostate intensity-modulated radiotherapy planning |
Q87671063 | The role of TRAIL in fatigue induced by repeated stress from radiotherapy |
Q39375431 | Toxicity and efficacy of three dose-fractionation regimens of intensity-modulated radiation therapy for localized prostate cancer |
Q55379685 | Urethra-sparing stereotactic body radiotherapy for prostate cancer: how much can the rectal wall dose be reduced with or without an endorectal balloon? |
Q36015152 | Urethrogram-Directed Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer in Patients with Contraindications to Magnetic Resonance Imaging |
Q39772182 | Use of stereotactic body radiotherapy for prostate cancer in the United States from 2004 through 2012. |
Q39736576 | Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer. |
Q43271415 | Utilization of Patient-Reported Outcomes to Guide Symptom Management during Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer |
Q36535570 | Volumetric-modulated arc stereotactic body radiotherapy for prostate cancer: dosimetric impact of an increased near-maximum target dose and of a rectal spacer. |
Q38412788 | What is the best way to radiate the prostate in 2016? |
Search more.